secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001193125-24-028372
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus prices $350M ADS offering at $6.00 per ADS for obe-cel development
--------------------------------------------------------------------------

- Offering of 58,333,336 ADSs at $6.00/ADS for gross proceeds of $350 million.
- Net proceeds to fund obe-cel clinical development, manufacturing, and commercial infrastructure.
- Additionally expects $250 million from BioNTech under license/option agreement and private placement.
- Offering expected to close February 12, 2024; Jefferies and Truist are joint bookrunners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000119312524028372/0001193125-24-028372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000119312524028372/d745010d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-028372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer